WO2004073641A3 - Induced activation in dendritic cells - Google Patents

Induced activation in dendritic cells Download PDF

Info

Publication number
WO2004073641A3
WO2004073641A3 PCT/US2004/004757 US2004004757W WO2004073641A3 WO 2004073641 A3 WO2004073641 A3 WO 2004073641A3 US 2004004757 W US2004004757 W US 2004004757W WO 2004073641 A3 WO2004073641 A3 WO 2004073641A3
Authority
WO
WIPO (PCT)
Prior art keywords
dendritic cells
induced activation
present
express
enhance
Prior art date
Application number
PCT/US2004/004757
Other languages
French (fr)
Other versions
WO2004073641A2 (en
Inventor
Kevin Slawin
David Spencer
Brent Hanks
Original Assignee
Kevin Slawin
David Spencer
Brent Hanks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kevin Slawin, David Spencer, Brent Hanks filed Critical Kevin Slawin
Priority to ES04712328.6T priority Critical patent/ES2543084T3/en
Priority to CA2516320A priority patent/CA2516320C/en
Priority to EP15157213.8A priority patent/EP2933334B1/en
Priority to EP04712328.6A priority patent/EP1641927B1/en
Publication of WO2004073641A2 publication Critical patent/WO2004073641A2/en
Publication of WO2004073641A3 publication Critical patent/WO2004073641A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)

Abstract

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co­stimulatory polypeptide.
PCT/US2004/004757 2003-02-18 2004-02-18 Induced activation in dendritic cells WO2004073641A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES04712328.6T ES2543084T3 (en) 2003-02-18 2004-02-18 Induced activation in dendritic cells
CA2516320A CA2516320C (en) 2003-02-18 2004-02-18 Induced activation in dendritic cells
EP15157213.8A EP2933334B1 (en) 2003-02-18 2004-02-18 Induced activation in dendritic cells
EP04712328.6A EP1641927B1 (en) 2003-02-18 2004-02-18 Induced activation in dendritic cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44804603P 2003-02-18 2003-02-18
US60/448,046 2003-02-18

Publications (2)

Publication Number Publication Date
WO2004073641A2 WO2004073641A2 (en) 2004-09-02
WO2004073641A3 true WO2004073641A3 (en) 2005-03-24

Family

ID=32908530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004757 WO2004073641A2 (en) 2003-02-18 2004-02-18 Induced activation in dendritic cells

Country Status (6)

Country Link
US (7) US7404950B2 (en)
EP (3) EP2557164A1 (en)
CA (1) CA2516320C (en)
ES (1) ES2543084T3 (en)
HK (1) HK1215451A1 (en)
WO (1) WO2004073641A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208849A1 (en) 2017-05-09 2018-11-15 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404950B2 (en) * 2003-02-18 2008-07-29 Baylor College Of Medicine Induced activation in dendritic cell
SE0301109D0 (en) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
EP1861161A4 (en) * 2005-01-24 2012-05-16 Neurosystec Corp Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
KR20080100353A (en) * 2006-02-01 2008-11-17 더 존스 홉킨스 유니버시티 Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US8267905B2 (en) * 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
CN104357469B (en) * 2006-05-03 2018-10-26 科罗拉多州立大学董事会 The combination of CD40 agonist antibody/type 1 interferon synergistic adjuvants includes conjugate above-mentioned and application thereof
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US7803148B2 (en) 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
EP2056793A4 (en) * 2006-07-31 2011-08-17 Neurosystec Corp Free base gacyclidine nanoparticles
EP2076272B1 (en) * 2006-10-19 2015-07-29 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
WO2008144616A1 (en) * 2007-05-18 2008-11-27 Heidi Kay Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
US8895610B1 (en) 2007-05-18 2014-11-25 Heldi Kay Platinum (IV) compounds targeting zinc finger domains
CA2695385A1 (en) * 2007-07-31 2009-02-05 Atul Bedi Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
EP2192925A4 (en) * 2007-08-23 2013-04-03 Keren Pharmaceuticals Targeting rna with external guide sequences
DK2331680T3 (en) * 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
RU2573912C2 (en) 2008-10-08 2016-01-27 Интрексон Корпорейшн Constructed cells, expressing multiple immunomodulators, and thereof application
WO2011043830A2 (en) * 2009-10-09 2011-04-14 New York University Methods, agents and peptides for inducing an innate immune response in hiv vaccination
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
AU2011239569B2 (en) * 2010-04-16 2014-07-24 Baylor College Of Medicine Method for treating solid tumors
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
WO2012047175A1 (en) * 2010-10-05 2012-04-12 Kemijski inštitut Fusion polypeptides comprising tir and dimerization domain for modulation of tlr/innate immunity signaling
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
WO2014039961A1 (en) 2012-09-07 2014-03-13 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
CN110423282B (en) 2013-02-15 2023-09-08 加利福尼亚大学董事会 Chimeric antigen receptor and methods of use thereof
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
SG11201506974XA (en) 2013-03-14 2015-10-29 Bellicum Pharmaceuticals Inc Methods for controlling t cell proliferation
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
CN111849912B (en) 2014-02-14 2024-03-15 贝里坤制药股份有限公司 Method for activating T cells using inducible chimeric polypeptides
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
AU2015341481C1 (en) 2014-11-03 2021-09-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T cell receptors directed against Bob1 and uses thereof
EP3608408A1 (en) 2014-12-15 2020-02-12 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
EP3262166A4 (en) 2015-02-24 2018-08-15 The Regents of The University of California Binding-triggered transcriptional switches and methods of use thereof
KR20180096788A (en) 2016-01-08 2018-08-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Conditionally-active heterodimeric polypeptides and methods for their use
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2018378955A1 (en) 2017-12-08 2020-06-18 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining CAR-T cell efficacy
EP3728189A1 (en) 2017-12-20 2020-10-28 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
FR2610631B1 (en) 1987-02-09 1989-11-24 Pasteur Institut MOLECULES COMPRISING AT LEAST ONE OR MORE SEARCHING PEPTIDE SEQUENCE, CHARACTERISTIC EPITOPE OF A PROTEIN PRODUCED BY P. FALCIPARUM IN HEPATOCYTES, AND USES THEREOF, IN PARTICULAR FOR MALARIA DIAGNOSIS OR VACCINE COMPOSITIONS AGAINST PALUDIS
US5869608A (en) 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
DE69233441T2 (en) 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Human cell surface antigen encoding DNA
US5780036A (en) 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
DE4228457A1 (en) 1992-08-27 1994-04-28 Beiersdorf Ag Production of heterodimeric PDGF-AB using a bicistronic vector system in mammalian cells
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5348253A (en) * 1993-02-01 1994-09-20 Gratzer Louis B Blended winglet
US5834266A (en) * 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5830462A (en) * 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5869337A (en) * 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
CA2155728C (en) * 1993-02-12 2000-04-25 Gerald R. Crabtree Regulated transcription of targeted genes and other biological events
US5426027A (en) 1993-05-20 1995-06-20 The Government Of The United States Of America As Represented By The Secretary Nucleic acid probes and methods for detecting Candida DNA cells in blood
US5648226A (en) 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
EP0721341A4 (en) 1993-08-06 1998-04-22 Cytel Corp Cloning and characterization of the complete mage-1 gene
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
FR2722208B1 (en) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
JPH11511643A (en) 1994-10-25 1999-10-12 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニア・ユニバーシティ Conditional transformation of genetically engineered cells
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
NZ333607A (en) * 1996-07-10 2000-08-25 Immunex Corp Method of stimulating the immune system by transfecting dendritic cells
US5955596A (en) 1996-07-26 1999-09-21 American Cyanamid Company NucA protein of Haemophilus influenzae and the gene encoding that protein
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US5965242A (en) 1997-02-19 1999-10-12 Eastman Kodak Company Glow-in-the-dark medium and method of making
US5995596A (en) 1997-03-12 1999-11-30 Siemens Information And Communication Networks, Inc. System and method for coordination of multimedia messages across multiple systems
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US20040040047A1 (en) 1998-03-30 2004-02-26 Spencer David M. Regulated apoptosis using chemically induced dimerization of apoptosis factors
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US20030108527A1 (en) 1999-12-28 2003-06-12 Tsukasa Seya Maturation-promoting agent for immature dendrtic cells
US7435585B2 (en) * 2000-01-03 2008-10-14 University Of Pennsylvania Auto-stimulating cells and methods for making and using the same
SE0001642D0 (en) 2000-05-04 2000-05-04 Sahltech Ab Reagent for detection of biomolecules, and use thereof
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
AU2001281252A1 (en) * 2000-08-10 2002-02-18 Board Of Regents, The University Of Texas System The tumor suppressor car-1
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6838263B2 (en) * 2001-07-09 2005-01-04 Oklahoma Medical Research Foundation Targeted fusion proteins and methods for the characterization of cellular membrane domains
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
AU2002353890A1 (en) * 2001-10-26 2003-05-06 Cleveland Clinic Foundation Fused cells, methods of forming same, and therapie utilizing same
WO2003078575A2 (en) 2002-03-11 2003-09-25 The Johns Hopkins University Molecular switches and methods for making and using the same
US7404950B2 (en) 2003-02-18 2008-07-29 Baylor College Of Medicine Induced activation in dendritic cell
ATE458500T1 (en) 2003-11-14 2010-03-15 Genvec Inc PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF LOCALLY ADVANCED PRIMARY INOPERABLE PANCREATIC CARCINOMA (LAPC).
US20080274140A1 (en) * 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
KR100705981B1 (en) * 2005-10-12 2007-04-10 주식회사 리제론 Compositions comprising human growth hormone for preventing hair loss or stimulating hair sprouting
US20100196336A1 (en) * 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP2076272B1 (en) * 2006-10-19 2015-07-29 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
KR101811965B1 (en) * 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. Antibodies that bind human dendritic and epithelial cell 205(dec-205)
AU2009221915A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
WO2009151503A2 (en) 2008-04-10 2009-12-17 University Of Florida Research Foundation, Inc. Compositions and methods for the treatment of a neoplasia
DK2331680T3 (en) 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
AU2011239569B2 (en) * 2010-04-16 2014-07-24 Baylor College Of Medicine Method for treating solid tumors
PT3214091T (en) 2010-12-09 2019-01-11 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013078433A1 (en) 2011-11-23 2013-05-30 University Of Hawaii Auto-processing domains for polypeptide expression
MX359257B (en) 2012-05-04 2018-09-19 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens.
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
SG11201506974XA (en) 2013-03-14 2015-10-29 Bellicum Pharmaceuticals Inc Methods for controlling t cell proliferation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHIODONI C. ET AL.: "Dendritic cells infiltrating tumors cotransuced with GM-CSF and CD40 ligand take up and present endogenous tumor-associated antigens, and prime naive mice for a CTL response", J. EXP. MED., vol. 190, 1999, pages 125 - 133, XP002308453 *
GRUIJL ET AL.: "Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors", J. IMMUNOL., vol. 169, 2002, pages 5322 - 5331, XP002983385 *
RICHARD R. ET AL.: "Expansion of genetically modified primary humanhemopoietic cells using chemical inducers of dimerization", BLOOD, vol. 95, 2000, pages 430 - 436, XP002983386 *
RIVERA V.: "Controlling gene expression using synthetic ligands", METHODS, vol. 14, 1998, pages 421 - 429, XP004466621 *
TONG ET AL.: "Prospects for CD40-directed experimental therapy of human cancer", CANCER GENE THER., vol. 10, 2003, pages 1 - 13, XP008042378 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208849A1 (en) 2017-05-09 2018-11-15 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction

Also Published As

Publication number Publication date
EP1641927A4 (en) 2006-11-02
EP1641927A2 (en) 2006-04-05
ES2543084T3 (en) 2015-08-14
EP2933334B1 (en) 2019-09-18
US20170182140A1 (en) 2017-06-29
US20200197502A1 (en) 2020-06-25
US9572835B2 (en) 2017-02-21
CA2516320C (en) 2015-05-26
US20040209836A1 (en) 2004-10-21
US8771671B2 (en) 2014-07-08
WO2004073641A2 (en) 2004-09-02
US7404950B2 (en) 2008-07-29
US10420824B2 (en) 2019-09-24
CA2516320A1 (en) 2004-09-02
EP1641927B1 (en) 2015-07-08
US20080269160A1 (en) 2008-10-30
US8999949B2 (en) 2015-04-07
EP2933334A1 (en) 2015-10-21
US20220233670A1 (en) 2022-07-28
EP2557164A1 (en) 2013-02-13
US20130183333A1 (en) 2013-07-18
US20150306140A1 (en) 2015-10-29
HK1215451A1 (en) 2016-08-26

Similar Documents

Publication Publication Date Title
WO2004073641A3 (en) Induced activation in dendritic cells
WO2004001019A3 (en) Novel nanoparticles and use thereof
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
WO2005042029A3 (en) Psma formulations and uses thereof
WO2003093441A3 (en) A method of regulating gene expression
TW200602491A (en) Human GLP-1 mimetibodies, compositions, methods and uses
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
MY163480A (en) Sclerostin binding agents
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
WO2005120524A3 (en) Nutritional formulations
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
WO2005070959A3 (en) Compositions comprising immune response altering agents and methods of use
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
GB0320020D0 (en) Improved formulation for providing an enteric coating material
MY128138A (en) Method for fighting against arthropods destructive of crops and compositions therefor
WO2004031105A3 (en) Use of a33 antigens and jam-it
WO2004067567A3 (en) Anti-dengue virus antibodies, compositions, methods and uses
WO2008080091A3 (en) Activation of rig-i pathway

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2516320

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004712328

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004712328

Country of ref document: EP